BRPI0410649A - benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k - Google Patents

benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k

Info

Publication number
BRPI0410649A
BRPI0410649A BRPI0410649-0A BRPI0410649A BRPI0410649A BR PI0410649 A BRPI0410649 A BR PI0410649A BR PI0410649 A BRPI0410649 A BR PI0410649A BR PI0410649 A BRPI0410649 A BR PI0410649A
Authority
BR
Brazil
Prior art keywords
heteroaryloxy
thiophene
aryloxy
therapeutic agents
substituted benzo
Prior art date
Application number
BRPI0410649-0A
Other languages
English (en)
Inventor
Michelle Marie Bruendl
Michael Kevin Connolly
Annise Paige Goodman
Rocco Dean Gogliotti
Helen Tsenwhei Lee
Mark Stephen Plummer
Karen Elaine Sexton
Gregory Adam Reichard
Melean Visnick
Michael William Wilson
Aurash Bavarsad Shahripour
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0410649A publication Critical patent/BRPI0410649A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

"BENZO(B) TIOFENOS 3-ARILóXI E 3-HETEROARILóXI SUBSTITUìDOS COMO AGENTES TERAPêUTICOS COM ATIVIDADE PI3K". A presente invenção proporciona benzo¢b! tiofenos de Fórmula (I), onde R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬, R¬ 5¬ e L possuem qualquer dos valores definidos para essa finalidade na especificação, e seus sais farmaceuticamente aceitáveis, que são úteis como agentes no tratamento de doenças e condições, incluindo doenças inflamatórias, doenças cardiovasculares, e cânceres. Também são providas composições farmacêuticas que compreendem um ou mais dos compostos de Fórmula (I).
BRPI0410649-0A 2003-06-05 2004-06-04 benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k BRPI0410649A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47597003P 2003-06-05 2003-06-05
PCT/IB2004/001823 WO2004108715A1 (en) 2003-06-05 2004-06-04 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity

Publications (1)

Publication Number Publication Date
BRPI0410649A true BRPI0410649A (pt) 2006-07-04

Family

ID=33511738

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410649-0A BRPI0410649A (pt) 2003-06-05 2004-06-04 benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k

Country Status (9)

Country Link
US (1) US20040259926A1 (pt)
EP (1) EP1636213B1 (pt)
JP (1) JP2006526611A (pt)
AT (1) ATE364605T1 (pt)
BR (1) BRPI0410649A (pt)
CA (1) CA2527576A1 (pt)
DE (1) DE602004006994T2 (pt)
ES (1) ES2285462T3 (pt)
WO (1) WO2004108715A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
FR2862645B1 (fr) * 2003-11-20 2007-06-22 Merck Sante Sas Composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2567883A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
EP2098226A1 (de) * 2008-03-06 2009-09-09 Forschungsverbund Berlin e.V. AKAP-PKA-Interaktionshemmer zur Anwendung in der Behandlung von Herzkrankheiten
KR20160091440A (ko) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
SG175259A1 (en) * 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
JP5739334B2 (ja) * 2009-08-26 2015-06-24 武田薬品工業株式会社 縮合複素環誘導体およびその用途
EA025407B1 (ru) 2012-03-05 2016-12-30 Джилид Калистога Ллс Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
US8877766B2 (en) * 2013-02-15 2014-11-04 Peter F. Kador Neuroprotective multifunctional antioxidants and their monofunctional analogs
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
NZ720867A (en) 2013-12-20 2018-01-26 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
WO2019073031A1 (en) 2017-10-13 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) POLYTHERAPY OF PANCREATIC CANCER
US12000833B2 (en) 2017-11-23 2024-06-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Marker for predicting the sensitivity to PI3K inhibitors
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954748A (en) * 1968-07-29 1976-05-04 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France 3-Alkoxy-thianapthene-2-carboxamides
US4703053A (en) * 1985-10-28 1987-10-27 Warner-Lambert Company Benzothiophenes and benzofurans and antiallergic use thereof
US4800211A (en) * 1986-08-18 1989-01-24 Merck & Co., Inc. 5-methylthio-3-hydroxybenzo [b]thiophene-2-carboxamide derivatives as cyclooxygenase and lipoxygenase inhibitors
US4767776A (en) * 1987-02-20 1988-08-30 Warner-Lambert Company N-1H-tetrazol-5-yl-2-naphthalene carboxamides and their use as antiallergy and antiinflammatory agents
US4764525A (en) * 1987-02-25 1988-08-16 Warner-Lambert Company N-1H-tetrazol-5-ylbenzamides having use as antiallergy and antiinflammatory agents
IE64995B1 (en) * 1987-07-14 1995-09-20 Warner Lambert Co Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome
US4910317A (en) * 1987-07-14 1990-03-20 Warner-Lambert Company Benzofurans and benzothiophenes having antiallergic activity and method of use thereof
US4931459A (en) * 1987-07-14 1990-06-05 Warner-Lambert Company Method for treating acute respirator distress syndrome
WO1992004321A1 (en) * 1990-09-10 1992-03-19 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5208253A (en) * 1992-02-24 1993-05-04 Warner-Lambert Company 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo(b) thiophene-2-carboxamides as inhibitors of cell adhesion
US5426113A (en) * 1994-04-08 1995-06-20 Warner-Lambert Company Method of preventing ulcer formation caused by nonsteroidal antiinflammatory drugs employing tetrazol-benzothiophene carboxamide compounds
HRP950288A2 (en) * 1994-05-31 1997-08-31 Bayer Ag Oxalylamino-benzofuran- and benzothienyl-derivatives
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
EP0765668B1 (fr) * 1995-09-07 1999-03-17 L'oreal Extrait d'iridacees et compositions le contenant
AR022889A1 (es) * 1999-03-12 2002-09-04 Bayer Cropscience Ag Agente desfoliante
DE19911165B4 (de) * 1999-03-12 2008-03-13 Bayer Cropscience Ag Entlaubungsmittel
EP1857443B1 (en) * 2000-01-24 2012-03-28 AstraZeneca AB Therapeutic morpholino-substituted compounds
GB0004699D0 (en) * 2000-02-28 2000-04-19 Merck Sharp & Dohme Chemical synthesis
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives

Also Published As

Publication number Publication date
DE602004006994T2 (de) 2008-02-14
CA2527576A1 (en) 2004-12-16
EP1636213B1 (en) 2007-06-13
JP2006526611A (ja) 2006-11-24
WO2004108715A8 (en) 2005-12-01
DE602004006994D1 (en) 2007-07-26
WO2004108715A1 (en) 2004-12-16
EP1636213A1 (en) 2006-03-22
ES2285462T3 (es) 2007-11-16
US20040259926A1 (en) 2004-12-23
ATE364605T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
ATE364605T1 (de) 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität
MXPA05013061A (es) Benzotiofenos sustituidos con cicloalquilos y heterocicloalquilos como agentes terapeuticos.
MXPA05012894A (es) Benzofuranos 3-sustituidos como agentes terapeuticos.
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
DE60045508D1 (de) Dalda-analoge und ihre verwendung
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
ECSP066311A (es) Derivados de la piperazina y su uso como agentes terapéuticos
PT939627E (pt) Pentafluorobenzenossulfonamidas e analogos
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
ATE444066T1 (de) Liganden für den cannabinoidrezeptoren
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
SE0402762D0 (sv) Indazole sulphonamide derivatives
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
ATE388708T1 (de) Piperazinderivate und anwendungsverfahren
CO5700775A2 (es) Nuevos derivados triciclicos como antagonistas de ltd4
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0407335A (pt) Agentes antibacterianos
BR0110255A (pt) Cromenilmetil pirimidinadiaminas como agentes antibacterianos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.